BFM
FATE icon

Boothbay Fund Management’s Fate Therapeutics FATE Stock Holding History

Boothbay Fund Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,666
Closed -$17.6K – 1522
2024
Q4 		$17.6K Buy
+10,666
New +$26.9K ﹤0.01% 1424
2019
Q2 		– Sell
-36,800
Closed -$647K – 783
2019
Q1 		$647K Buy
+36,800
New +$581K 0.06% 316

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Boothbay Fund Management's FATE Position: Q1 2025 in Review

Boothbay Fund Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 10,666 shares — an estimated $17.6K sold.

Boothbay Fund Management first reported a position in FATE in Q1 2019 and held it in 2 quarters. The position peaked at $647K in Q1 2019. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Boothbay Fund Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 10,666 Fate Therapeutics shares in Q1 2025, an estimated $17.6K.
  • Boothbay Fund Management first reported a position in Fate Therapeutics in Q1 2019 and held it in 2 quarters.
  • Boothbay Fund Management's Fate Therapeutics position peaked at $647K in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.